In vitro evaluation of contemporary β-lactam drugs tested against viridans group and β-haemolytic streptococci

Diagnostic Microbiology and Infectious Disease

Volumn 27, Issue 4, 1997, Pages 151-154

  Pfaller, Michael A ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; TIMENTIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BETA HEMOLYTIC STREPTOCOCCUS; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STANDARD;

AMPICILLIN; ANTI-BACTERIAL AGENTS; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORINS; DRUG RESISTANCE, MICROBIAL; MICROBIAL SENSITIVITY TESTS; PENICILLINS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; TICARCILLIN;

EID: 0030998233     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00032-1     Document Type: Article

References (12)

1. Alcaide F, Linares J, Pallanes R, Carratala J, Benitez MA, Gudiol F, Martin R (1995) In vitro activities of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci from blood. Antimicrob Agents Chemother 39:2243-3347.
2. Appelbaum PC (1992) Antibiotic resistance in Streptococcus pneumoniae: An overview. Clin Infect Dis 15:77-83.
3. Biedenbach DJ, Jones RN (1996) The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagn Microbiol Infect Dis, 25:47-51.
4. Bochud PY, Eggeman P, Calandra T, Van Melle G, Saghafi L, Francioli P (1994) Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin Infect Dis 18:25-31.
5. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL (1996) Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother 40:891-894.
6. Johnson DM, Doern GV, Haugen TA, Hindler J, Washington JA, Jones RN (1996) Comparative activity of twelve β-lactam drugs tested against penicillin-resistant Streptococcus pneumoniae from five medical centers: Effects of serum protein and capsular material on potency and spectrum as measured by reference tests. Diagn Microbiol Infect Dis 25:137-141.
7. Jones RN (1995) Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: A review. Diagn Microbiol Infect Dis 22:19-33.
8. Jones RN, Kehrberg EN, Erwin Me, Anderson SC (1994) Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous centers in the United States. I. Study on the threat of emerging resistances: Real or perceived? Diagn Microbiol Infect Dis 19:203-215.
9. McWhinney PHM, Patel S, Whiley RA, Hardie JM, Gillespie SH, Kibbler CC (1993) Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. Antimicrob Agents Chemother 37:2493-2495.
10. National Committee for Clinical Laboratory Standards (NCCLS) (1993) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A3. Villanova, PA: NCCLS.
11. National Committee for Clinical Laboratory Standards (NCCLS) (1995) Performance standards for antimicrobial susceptibility testing: 6th international supplement, M100-S6. Villanova, PA: NCCLS.
12. Venditti M, Baicocchi P, Santini C, Brandimarte C, Serra P, Gentile G, Girmenia C, Marteno P (1989) Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients. Antimicrob Agents Chemother 33:580-5823.